Integrated proteomics and machine learning reveal AHNAK as a discriminative biomarker of atrial fibrillation in heart failure.
A blood protein biomarker helps spot heart failure patients developing dangerous irregular heartbeat, supporting personalized rhythm management.
This study applied integrated plasma proteomics combined with machine learning to discover and validate AHNAK as a discriminative biomarker for atrial fibrillation in heart failure patients, where AF is a major complication substantially worsening prognosis. AHNAK-based AF risk stratification in HF could improve patient phenotyping, guide monitoring strategies, and inform personalized rhythm management decisions.
What the study was
- Study design
- Multi-omics discovery and validation study (proteomics + ML)
- Population
- Heart failure patients with and without atrial fibrillation complication
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- BMC Med
Why it surfaced
Integrated proteomics-ML biomarker discovery for AF-in-HF addresses a high-burden clinical problem; AHNAK is a novel candidate requiring further prospective validation but represents a meaningful precision cardiology advance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.